Concepedia

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

David F. McDermott, Jeffrey A. Sosman, René González, F. Stephen Hodi, Gerald P. Linette, Jon Richards, James W. Jakub, Muralidhar Beeram, Stefano Tarantolo, Sanjiv S. Agarwala,

Journal of Clinical Oncology · 2008 · 249 citations · 22 references

DOI

Abstract

Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS. Based on these findings, additional studies with the combination are warranted in this patient population.

References

22

Mutations of the BRAF gene in human cancer

Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.6K citations · Full text

, , +5

Cancer Statistics, 2007

Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text

, , +13

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

, , +12

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson et al. · Journal of Clinical Oncology · 2000 · 1.3K citations

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

Paul B. Chapman, Lawrence H. Einhorn, Michael L. Meyers et al. · Journal of Clinical Oncology · 1999 · 758 citations